Quarterly ResultJun 15, 2026, 04:22 PM
Zeo ScientifiX Reports $4.03M Revenue, Reduced Net Loss in 10-Q Filing
AI Summary
Zeo ScientifiX, Inc. (ZEOX) filed its Form 10-Q for the period ending April 30, 2026. The company reported a significant increase in revenues to $4,027,000 for the first six months of the fiscal year, up from $2,239,000 in the prior year. This revenue growth contributed to a reduced net loss of $997,000, an improvement from $2,634,000 in the same period last year. The company also recognized a $390,000 gain from the sale of its Exotropin interests. Despite these improvements, the company continues to face challenges related to its going concern status, with substantial doubt expressed about its ability to continue operations without additional funding.
Key Highlights
- Zeo ScientifiX reported a net loss of $997,000 for the six months ended April 30, 2026, compared to a net loss of $2,634,000 for the same period in 2025.
- Revenues increased to $4,027,000 for the six months ended April 30, 2026, up from $2,239,000 in the prior year.
- The company recorded a gain of $390,000 from the sale of its Exotropin interests.
- Total assets grew to $3,886,000 as of April 30, 2026, from $1,527,000 as of October 31, 2025.
- Cash increased significantly to $1,846,000 as of April 30, 2026, from $221,000 as of October 31, 2025.
- Stockholders' equity (deficit) improved to $712,000 from a deficit of $1,423,000.
- Net loss per common share improved to ($0.14) for the six months ended April 30, 2026, from ($0.42) in the prior year.
Price Impact
More from ZEOX